A Double-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Men and Women With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs HM 12525A (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Janssen Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2017 Status changed from suspended to discontinued due to manufacturing-related issues.
- 30 Nov 2016 Status changed from recruiting to suspended.